Epidiolex Shortage: What Providers and Prescribers Need to Know in 2026

For neurologists, epileptologists, and other prescribers managing patients with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC), Epidiolex has been a meaningful addition to the antiseizure medication (ASM) landscape since its FDA approval in 2018. However, getting patients successfully onto Epidiolex requires navigating a complex access ecosystem — one that involves specialty pharmacy logistics, insurance prior authorization, and robust patient support programs. Here is what you need to know in 2026.

Current Supply Status: No FDA Shortage, But Access Challenges Persist

Epidiolex is not on the FDA's drug shortage database as of 2026. Jazz Pharmaceuticals has not reported manufacturing disruptions. The challenges your patients face accessing Epidiolex are systemic — arising from the specialty pharmacy distribution model, insurance prior authorization requirements, and cost barriers — not from supply chain failures.

This distinction matters clinically: there is no need to preemptively switch patients to alternative agents out of shortage concerns. The appropriate response to access delays is to activate available support programs, not to alter an otherwise effective treatment plan.

Understanding the Specialty Pharmacy Distribution Model

Epidiolex is exclusively distributed through specialty pharmacies — not standard retail pharmacy networks. When you prescribe Epidiolex, the prescription is routed to a specialty pharmacy that is in-network for the patient's insurance plan. Key implications for your practice:

The specialty pharmacy will contact the patient directly — counsel patients to expect calls from unfamiliar numbers after you submit the prescription

Delivery is typically by mail — patients generally do not pick up Epidiolex in person

Different insurance plans mandate different specialty pharmacies — ensure your staff are not sending prescriptions to a pharmacy not in the patient's network

JazzCares (1-833-426-4243) can identify the correct specialty pharmacy for each patient's plan — consider enrolling patients in JazzCares at the time of prescription

Prior Authorization: What Your Office Needs to Know

Prior authorization is nearly universal for Epidiolex. Most commercial plans and government programs (Medicare Part D, Medicaid) require PA before approving coverage. The typical timeline is 2 to 4 weeks, though appeals can extend this significantly. To support faster PA approvals:

Include the specific ICD-10 diagnosis code in your prescription (G40.811/G40.812 for Dravet, G40.411/G40.412 for LGS, Q85.1 for TSC)

Document prior antiseizure medication trials and outcomes — step therapy requirements are common on commercial and Medicaid plans

Submit the PA at the same time as the prescription — simultaneous submission reduces total time to fill

JazzCares offers dedicated PA support specialists who can assist your office staff with navigating the review process and appeals

The JazzCares Quick Start Program: Bridging Insurance Delays

One of the most important tools for managing access delays is the JazzCares Quick Start Program. This provides eligible patients with up to four 15-day free supplies (60 days total) of Epidiolex while awaiting insurance approval. Key details:

Available to commercially insured patients as well as Medicare, Medicaid, and VA beneficiaries experiencing a coverage delay

Patient must be enrolled in the JazzCares Patient Support Program

One Quick Start per patient lifetime (lifetime limit)

A valid, signed prescription is required — cash-pay patients are not eligible for Quick Start

According to Jazz, approximately 90% of patients who begin the Quick Start program obtain insurance coverage within 30 days, making it an effective bridge for the PA period.

Clinical Monitoring Requirements

Remember the boxed warning: Epidiolex can cause dose-related transaminase elevations, particularly in patients also taking valproate. Per the prescribing information, obtain liver function tests (LFTs) — transaminase and bilirubin — before initiating Epidiolex, then at 1 month, 3 months, and 6 months after initiation, and periodically thereafter.

ALT >3x ULN: consider dose reduction of Epidiolex, valproate, or clobazam

ALT >3x ULN + bilirubin >2x ULN: discontinue Epidiolex

ALT >5x ULN sustained: discontinue Epidiolex

If patients are on concomitant valproate and/or clobazam, transaminase monitoring becomes especially important. Elevated ammonia levels have also been reported postmarketing in patients with transaminase elevations, most commonly in those on concomitant valproate and/or clobazam.

Key Drug Interactions to Flag for Your Patients

Clobazam: Epidiolex significantly increases N-desmethylclobazam (active metabolite) levels by approximately 3-fold. Monitor for somnolence; clobazam dose reduction may be needed.

Valproate: Markedly increases risk of hepatotoxicity. Monitor LFTs closely when these two agents are combined.

Everolimus (TSC patients): Cannabidiol significantly increases everolimus exposure. A lower starting dose and careful therapeutic drug monitoring is recommended when these agents are co-administered.

CYP3A4 inducers (e.g., carbamazepine, rifampin): May reduce cannabidiol plasma concentrations, potentially compromising efficacy.

How to Help Patients Who Are Having Trouble Filling Epidiolex

When patients call your office reporting they cannot get Epidiolex filled, direct them and your staff to: (1) call JazzCares at 1-833-426-4243 for insurance support and Quick Start enrollment, (2) use medfinder to identify specialty pharmacies in their area with available stock, and (3) refer to our provider guide on helping patients find Epidiolex for additional strategies.